Ticagrelor Tablet, Film Coated
Product Images NDC 0378-2215

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 0378-2215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ticagrelor Tablets 90 mg Bottle Label (Export 00)

Each Ticagrelor tablet contains 20 mg of active ingredient. The recommended adult dosage should be followed as per the accompanying prescribing information. It is vital to keep all medications out of children's reach and store them at a temperature between 20° to 25°C (68° to 77°F). The tablets are manufactured by Mylan Pharmaceuticals Inc., in the USA, but they are made in India. Pharmacists are advised to dispense the medication along with a Medication Guide to each patient. The tablets should be dispensed in a tightly sealed container with a child-resistant closure. Remember to keep the container tightly closed at all times.*

FDA Label Image

Ticagrelor Tablets 60 mg Bottle Label (Export 01)

FDA Label Image

Figure 18: Subgroup Analyses Of Ticagrelor 90 mg (thales) (Export 02)

FDA Label Image

Figure 17: Time To First Occurrence Of Stroke Or Death (thales) (Export 03)

FDA Label Image

Figure 16: Subgroup Analyses Of Ticagrelor (themis) (Export 04)

FDA Label Image

Figure 15: Time To First Occurrence Of Cv Death, Mi Or Stroke (themis) (Export 05)

FDA Label Image

Figure 14: Subgroup Analyses Of Ticagrelor 60 mg (pegasus) (Export 06)

FDA Label Image

Figure 13: Time To First Occurrence Of Cv Death, Mi Or Stroke (pegasus) (Export 07)

FDA Label Image

Figure 11: Subgroup Analyses Of (plato) (Export 08)

FDA Label Image

Figure 10: Time To First Occurrence Of Cv Death, Mi, Or Stroke (plato) (Export 09)

FDA Label Image

Figure 12: Cv Death, Mi, Stroke By Maintenance Aspirin Dose In The U.s. And Outside The U.s. (plato) (Export 10)

FDA Label Image

Figure 1: Kaplan-meier Estimate Of Time To First Non-cabg Plato-defined Major Bleeding Event (plato) (Image 01)

FDA Label Image

Figure 2: ‘major Fatal/life-threatening’ Cabg-related Bleeding By Days From Last Dose Of Study Drug To Cabg Procedure (plato) (Image 02)

FDA Label Image

Ticagrelor Structural Formula (Image 03)

FDA Label Image

Figure 5: Mean Inhibition Of Platelet Aggregation (± Se) Following Single Oral Doses Of Placebo, 180 mg Ticagrelor Or 600 mg Clopidogrel (Image 04)

This text provides information on the percentage of inhibition of platelet aggregation induced by 20uM ADP for Ticagrelor (180 mg) and Clopidogrel (600 mg) at different time intervals (hours). The data seems to be related to a study or experiment evaluating the effectiveness of these two antiplatelet medications.*

FDA Label Image

Figure 6: Mean Inhibition Of Platelet Aggregation (ipa) Following 6 Weeks On Placebo, Ticagrelor 90 mg Twice Daily, Or Clopidogrel 75 mg Daily (Image 05)

FDA Label Image

Figure 7: Impact Of Intrinsic Factors On The Pharmacokinetics Of Ticagrelor (Image 06)

FDA Label Image

Figure 3: Time To First Timi Major Bleeding Event (themis) (Image 07)

FDA Label Image

Figure 9: Impact Of Ticagrelor Tablets On The Pharmacokinetics Of Co-administered Drugs (Image 08)

This is a table showing drug interactions with Ticagrelor, along with recommendations on dose adjustment for various medications when used in combination with Ticagrelor. The table lists different drugs, their recommended doses, and whether any dose adjustment is required when combined with Ticagrelor. The text also mentions observations on the effects of Ticagrelor on the levels of various metabolites and highlights the need to monitor digoxin levels when initiating or changing Ticagrelor therapy.*

FDA Label Image

Figure 4: Time Course Of Gusto Severe Bleeding Events (Image 09)

FDA Label Image

Figure 7: Effect Of Co-administered Drugs On The Pharmacokinetics Of Ticagrelor (Image 16)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.